Eli Lilly warns against 'cosmetic' use of popular diabetes, obesity drugs
Drugmaker Eli Lilly on Thursday warned against using its diabetes and obesity drugs for “cosmetic” weight loss, as the medications have exploded in popularity, resulting in shortages. In an open letter posted online, the company said its products Mounjaro and Zepbound “are indicated for the treatment of serious diseases; they are not approved for —…